{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T06:20:34Z","timestamp":1758349234177,"version":"3.44.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,18]]},"DOI":"10.7759\/cureus.92674","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:17:38Z","timestamp":1758259058000},"source":"Crossref","is-referenced-by-count":0,"title":["An Integrative Analysis of O6-Methylguanine-DNA Methyltransferase (MGMT) Methylation and the Single-Nucleotide Polymorphism (SNP) rs1625649 Reveals Distinct Survival Patterns in Glioblastoma: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Krachi","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivanjali","family":"Raghuvanshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snehkiran","family":"Raghuvanshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BK","family":"Ojha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019","volume":"24","author":"Ostrom QT","year":"2022","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022, 24:v1-v95. 10.1093\/neuonc\/noac202","journal-title":"Neuro Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis DN","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, et al.. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016, 131:803-20. 10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, et al.. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021, 23:1231-51. 10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2305-5839.2016.01.25","article-title":"Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma","volume":"4","author":"Khosla D","year":"2016","unstructured":"Khosla D. Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med. 2016, 4:54. 10.3978\/j.issn.2305-5839.2016.01.25","journal-title":"Ann Transl Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X18666200626204005","article-title":"Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications","volume":"19","author":"Ortiz R","year":"2021","unstructured":"Ortiz R, Perazzoli G, Cabeza L, Jim\u00e9nez-Luna C, Luque R, Prados J, Melguizo C. Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Curr Neuropharmacol. 2021, 19:513-37. 10.2174\/1570159X18666200626204005","journal-title":"Curr Neuropharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01547","article-title":"O6-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy","volume":"9","author":"Yu W","year":"2019","unstructured":"Yu W, Zhang L, Wei Q, Shao A. O6-methylguanine-DNA methyltransferase (MGMT): challenges and new opportunities in glioma chemotherapy. Front Oncol. 2019, 9:1547. 10.3389\/fonc.2019.01547","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.02.010","article-title":"MGMT status as a clinical biomarker in glioblastoma","volume":"6","author":"Butler M","year":"2020","unstructured":"Butler M, Pongor L, Su YT, et al.. MGMT status as a clinical biomarker in glioblastoma. Trends Cancer. 2020, 6:380-91. 10.1016\/j.trecan.2020.02.010","journal-title":"Trends Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186430","article-title":"The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma","volume":"12","author":"Hsu CY","year":"2017","unstructured":"Hsu CY, Ho HL, Lin SC, Ho TD, Ho DM. The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma. PLoS One. 2017, 12:e0186430. 10.1371\/journal.pone.0186430","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18502\/ajmb.v15i1.11424","article-title":"MGMT gene rs1625649 polymorphism in Iranian patients with brain glioblastoma: a case control study","volume":"15","author":"Safaei R","year":"2023","unstructured":"Safaei R, Mojtahedi H, Hanaei S, et al.. MGMT gene rs1625649 polymorphism in Iranian patients with brain glioblastoma: a case control study. Avicenna J Med Biotechnol. 2023, 15:48-52. 10.18502\/ajmb.v15i1.11424","journal-title":"Avicenna J Med Biotechnol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-0814","article-title":"Validation of genetic markers associated with survival in colorectal cancer patients treated with oxaliplatin-based chemotherapy","volume":"31","author":"Park HA","year":"2022","unstructured":"Park HA, Seibold P, Edelmann D, et al.. Validation of genetic markers associated with survival in colorectal cancer patients treated with oxaliplatin-based chemotherapy. Cancer Epidemiol Biomarkers Prev. 2022, 31:352-61. 10.1158\/1055-9965.EPI-21-0814","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae108","article-title":"No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients","volume":"26","author":"Hegi ME","year":"2024","unstructured":"Hegi ME, Oppong FB, Perry JR, et al.. No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: reanalysis of the CE.6 and the pooled Nordic\/NOA-08 trials in elderly glioblastoma patients. Neuro Oncol. 2024, 26:1867-75. 10.1093\/neuonc\/noae108","journal-title":"Neuro Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25169-2","article-title":"Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (temozolomide)","volume":"8","author":"Pandith AA","year":"2018","unstructured":"Pandith AA, Qasim I, Zahoor W, et al.. Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (temozolomide). Sci Rep. 2018, 8:6704. 10.1038\/s41598-018-25169-2","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-03955-3","article-title":"Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma","volume":"157","author":"Haque W","year":"2022","unstructured":"Haque W, Teh C, Butler EB, Teh BS. Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma. J Neurooncol. 2022, 157:137-46. 10.1007\/s11060-022-03955-3","journal-title":"J Neurooncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10082030","article-title":"MGMT promoter methylation as a prognostic factor in primary glioblastoma: a single-institution observational study","volume":"10","author":"Szylberg M","year":"2022","unstructured":"Szylberg M, Sokal P, \u015aledzi\u0144ska P, et al.. MGMT promoter methylation as a prognostic factor in primary glioblastoma: a single-institution observational study. Biomedicines. 2022, 10:2030. 10.3390\/biomedicines10082030","journal-title":"Biomedicines"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071122","article-title":"Positive prognostic overall survival impacts of methylated TGFB2 and MGMT in adult glioblastoma patients","volume":"17","author":"Qazi S","year":"2025","unstructured":"Qazi S, Potts M, Myers S, Richardson S, Trieu V. Positive prognostic overall survival impacts of methylated TGFB2 and MGMT in adult glioblastoma patients. Cancers (Basel). 2025, 17:1122. 10.3390\/cancers17071122","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyaa449","article-title":"MGMT-positive vs MGMT-negative patients with glioblastoma: identification of prognostic factors and resection threshold","volume":"88","author":"Katsigiannis S","year":"2021","unstructured":"Katsigiannis S, Grau S, Krischek B, et al.. MGMT-positive vs MGMT-negative patients with glioblastoma: identification of prognostic factors and resection threshold. Neurosurgery. 2021, 88:E323-9. 10.1093\/neuros\/nyaa449","journal-title":"Neurosurgery"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1590\/s1807-59322011001000013","article-title":"Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma","volume":"66","author":"Uno M","year":"2011","unstructured":"Uno M, Oba-Shinjo SM, Camargo AA, et al.. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics (Sao Paulo). 2011, 66:1747-55. 10.1590\/s1807-59322011001000013","journal-title":"Clinics (Sao Paulo)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nop020","article-title":"MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma","volume":"12","author":"Rivera AL","year":"2010","unstructured":"Rivera AL, Pelloski CE, Gilbert MR, et al.. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010, 12:116-21. 10.1093\/neuonc\/nop020","journal-title":"Neuro Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","volume":"13","author":"Malmstr\u00f6m A","year":"2012","unstructured":"Malmstr\u00f6m A, Gr\u00f8nberg BH, Marosi C, et al.. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012, 13:916-26. 10.1016\/S1470-2045(12)70265-6","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt355","article-title":"Influence of promoter\/enhancer region haplotypes on MGMT transcriptional regulation: a potential biomarker for human sensitivity to alkylating agents","volume":"35","author":"Xu M","year":"2014","unstructured":"Xu M, Nekhayeva I, Cross CE, et al.. Influence of promoter\/enhancer region haplotypes on MGMT transcriptional regulation: a potential biomarker for human sensitivity to alkylating agents. Carcinogenesis. 2014, 35:564-71. 10.1093\/carcin\/bgt355","journal-title":"Carcinogenesis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1159\/000170088","article-title":"Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study","volume":"32","author":"Zawlik I","year":"2009","unstructured":"Zawlik I, Vaccarella S, Kita D, et al.. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology. 2009, 32:21-9. 10.1159\/000170088","journal-title":"Neuroepidemiology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/407660-an-integrative-analysis-of-o6-methylguanine-dna-methyltransferase-mgmt-methylation-and-the-single-nucleotide-polymorphism-snp-rs1625649-reveals-distinct-survival-patterns-in-glioblastoma-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:17:39Z","timestamp":1758259059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/407660-an-integrative-analysis-of-o6-methylguanine-dna-methyltransferase-mgmt-methylation-and-the-single-nucleotide-polymorphism-snp-rs1625649-reveals-distinct-survival-patterns-in-glioblastoma-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.92674","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}